Abstract
Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Current Pharmaceutical Design
Title:Current Rapid-Onset Antidepressants and Related Animal Models
Volume: 24 Issue: 22
Author(s): Kuo Yan, Yi-Bing Chen, Jia-Rong Wu, Kuang-Dai Li and Yuan-Lu Cui*
Affiliation:
- Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 88 YuQuan Road, Nankai District, Tianjin, 300193,China
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Abstract: Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Export Options
About this article
Cite this article as:
Yan Kuo, Chen Yi-Bing , Wu Jia-Rong, Li Kuang-Dai and Cui Yuan-Lu *, Current Rapid-Onset Antidepressants and Related Animal Models, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180727115222
DOI https://dx.doi.org/10.2174/1381612824666180727115222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Structure Solution of Misfolded Conformations Adopted by Intrinsically Disordered Alzheimers Tau Protein
Protein & Peptide Letters Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Aging Science Counter-Regulatory Role of Bile Acid Activated Receptors in Immunity and Inflammation
Current Molecular Medicine A Systematic Review of Economic Evaluation Studies of Drug-Based Non-Malignant Chronic Pain Treatment
Current Pharmaceutical Biotechnology Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry Possible Protecting Role of TNF-α in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NFκB Signaling Pathway
Current Alzheimer Research Editorial [Hot Topic: Molecular Pharmacology of the GABAA Receptor (Guest Editor: Gustav Akk)]
Current Neuropharmacology The Role of P-glycoprotein in Cerebral Amyloid Angiopathy; Implications for the Early Pathogenesis of Alzheimers Disease
Current Alzheimer Research Update to: The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?
Medicinal Chemistry Reviews - Online (Discontinued) The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Meet Our Editorial Board Member
Current Neuropharmacology Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach
Current Pharmaceutical Design Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target
Current Drug Targets Effects of Tetrahydroxystilbene Glucoside on Liver P450 Enzym e Expressions in Lipopolysaccharide-induced Dopamine Neuronal Dama ge Rats
Letters in Drug Design & Discovery CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry